fondaparinux
[용어속성] Drug
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
COVID-19 및 SARS-CoV-2 백신 접종에서의 응고증 및 섬유소 용해성 병태생리학
Review
[키워드] Activation
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
antibody
argatroban
bleeding
caused
cerebral venous sinuse
cerebral venous sinuses
characterized
Coagulation
Coagulopathy
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
D-dimer
decrease
decreases
Disseminated intravascular coagulation
enhanced-fibrinolytic-type DIC
enzyme
enzyme-linked immunosorbent
enzyme-linked immunosorbent assay
fibrinogen
fibrinolysis
fibrinolytic
fondaparinux
high risk
High-dose
immune
Immunoglobulin
IMPROVE
in some
increases in
intravascular coagulation
nafamostat
occur
outcomes
Platelet
Platelets
respiratory
resulting
SARS-CoV-2
SARS-CoV-2 vaccine
SARS-CoV-2 vaccines
severe acute respiratory syndrome Coronavirus
severe COVID-19
thrombosis
thrombotic
Thrombotic thrombocytopenia
Treatment
vaccination
visceral
[DOI] 10.3390/ijms23063338 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/ijms23063338 PMC 바로가기 [Article Type] Review
Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register
혈전 예방을 받는 COVID-19 환자의 낮은 병원 내 사망률: 다기관 관찰 START-COVID Register의 데이터
Observational Study
[키워드] Admission
affected
Antithrombotic
Atrial fibrillation
bleeding
Cancer
cause
characteristic
Cohort
Comorbidities
conducted
COVID-19
COVID-19 disease
COVID-19 infection
COVID-19 patient
Deep vein
Deep vein thrombosis
dosage
drug
DVT
enoxaparin
fondaparinux
heparin
high mortality rate
Hospital stay
Hospitalized
hospitalized patients
hypertension
in-hospital mortality rate
interstitial pneumonia
Italian
low molecular weight
low molecular weight heparin
major bleeding
majority
Mortality
mortality rate
mortality rates
multicentre
multivariable
multivariable analysis
Neurological disease
observational study
outcome
pathology
Patient
patients hospitalized
patients older
patients with COVID-19
Pulmonary embolism
receive
receiving
reduction
retrospective
severe interstitial pneumonia
significantly
survival
thromboembolic
thromboembolic disease
Thromboembolism
Thromboprophylaxis
thrombosis
thrombotic
thrombotic event
Thrombotic events
treated
Treatment
Venous Thromboembolism
[DOI] 10.1007/s11739-021-02891-w PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1007/s11739-021-02891-w PMC 바로가기 [Article Type] Observational Study
Heparin and SARS-CoV-2: Multiple Pathophysiological Links
Review
[키워드] adopted
Anticoagulant
bleeding
bleedings
condition
COVID-19
dose
drug
Extracellular matrix
fondaparinux
heparin
heparins
ICU
ICUs
increased risk
Inpatient
intensive care unit
low molecular weight heparin
molecular weight
Multiple
oligosaccharide
pandemic
Prevent
prolonged administration
recognize
recorded
reported
respiratory tract
the SARS-CoV-2
therapeutic dose
underlying disease
Venous Thromboembolism
virus
VTE
with COVID-19
[DOI] 10.3390/v13122486 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/v13122486 PMC 바로가기 [Article Type] Review
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients
입원한 코로나19 환자의 폐색전증 치료제 에독사반
Article
[키워드] Admission
Analysis
ARDS
baseline
clinical
clinical outcomes
computer tomography
conducted
COVID-19
edoxaban
effective
Efficacy
Follow-up
fondaparinux
Hospitalization
hospitalized COVID-19 patient
hospitalized COVID-19 patients
hospitalized patient
hospitalized patients
initial
institution
Multivariate analysis
outcome
Patient
patients with ARDS
Pulmonary embolism
Retrospective analysis
Safe
Safety
SARS-CoV-2
therapy
those without PE
treated
Treatment
with COVID-19
[DOI] 10.1080/17512433.2021.1964359 PMC 바로가기 [Article Type] Article
[DOI] 10.1080/17512433.2021.1964359 PMC 바로가기 [Article Type] Article
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial
입원한 COVID-19의 응고병증: COVID-19 유행병에 대한 신속한 대응으로서 치료용 항응고제 대 표준 치료의 실용적인 무작위 통제 시험(RAPID COVID COAG – RAPID 실험): 무작위 통제 실험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
absence
acutely ill hospitalized medical patients
Admission
age
allergy
allocation concealment
allocation sequence
Alpha
America
and protocol
Anticoagulant
anticoagulation
antiplatelet
antithrombotic therapy
apixaban
arterial
bleeding
bleeding risk
Blinding
block sizes
blood cell
Brazil
can not
Canada
Care
Chain Reaction
changed
choice
clinical trial
clinically
clinician
Coagulation
Coagulopathy
Committee
complex
Composite
computer-generated
contraindication
control group
Controlled
COVID
COVID-19
Critical
Critical illness
cryoprecipitate
D-dimer
D-dimer value
Dabigatran
dalteparin
Date
death
defined
dependent on
detect
determine
diagnosis of SARS-CoV-2
diagnostic
Diagnostic imaging
discretion
disorder
dissemination
dose
dual
edoxaban
electrocardiogram
element
elevated
emergency room
enoxaparin
Enrollment
evaluated
exclusion criteria
expected
experimental group
fibrinogen
fondaparinux
frozen plasma
Health Organization
hemoglobin
heparin
heparin-induced thrombocytopenia
High dose
high risk
hospital
Hospital admission
hospitalised
Hospitalized
hospitalized patient
hospitalized patients
ICU
ICU admission
include
inclusion criteria
indicated
individual
inflammatory biomarkers
Informed consent
INR
intensive care
intensive care unit
Interactive Web Response System
intermediate dose
Invasive mechanical ventilation
involved
Ireland
isothermal amplification
judgement
limit
LMWH
Local
low molecular weight
low molecular weight heparin
Major
major bleeding
mechanical ventilation
Non-invasive
non-invasive positive pressure ventilation
nucleic acid
number
objective
occur
Open-label
open-label trial
outcome
oxygen
oxygen saturation
participant
Patient
patients
Phase 3
plasma
Platelet
Platelet count
Platelets
polymerase chain
polymerase chain reaction
positive pressure
positive pressure ventilation
power
Pregnancy
pressure ventilation
protocol
random
random allocation
randomised
randomised controlled trial
randomization
Randomized controlled trial
Rapid
recruited
red blood cell
renal replacement therapy
replacement therapy
response
responsible
reverse transcriptase
Reverse transcriptase polymerase chain reaction
risk
risk difference
rivaroxaban
room air
Sample size
Saudi Arabia
secondary
Secondary outcomes
Standard
standard care
status
stratified
study population
Study protocol
supplementary material
symptomatic
the patient
the United State
therapeutic anticoagulation
therapeutic dose
therapy
thrombocytopenia
Thromboembolism
Thromboprophylaxis
tinzaparin
transcriptase
transfusion
treated
Trial
Trial registration
two-sided
ULN
unfractionated heparin
United Arab Emirates
United States
Venous Thromboembolism
Ventilator-free days
Version
Warfarin
website
World Health Organization
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study
Medicine
[키워드] acute respiratory distress
acute respiratory distress syndrome
anticoagulant therapy
bleeding event
Clinical characteristics
clinical impact
Clinical prognosis
clinically
COVID-19
COVID-19 patient
COVID-19 patients
cumulative
death
decreased mortality
Deep venous thrombosis
drug
Effectiveness
Efficacy
enoxaparin
enrolled
evaluate
event
Evidence
FIVE
Follow-up
fondaparinux
heparin
hospital
Hospitalized
hospitalized COVID-19 patients
hospitalized patient
incidence
incidence rate
interquartile
Italian
Laboratory
major bleeding
major bleedings
median
multicenter
observation
outcome
pharmacological
Prophylaxis
Prospective Study
provide
Pulmonary embolism
Regression model
retrospective
risk
Safe
setting
severe coronavirus disease
shown
significant difference
significant differences
statistically significant difference
symptomatic patient
syndrome
therapy
Thromboprofylaxis
Thromboprophylaxis
two group
Venous Thromboembolism
VTE
[DOI] 10.3389/fmed.2020.569567 PMC 바로가기 [Article Type] Medicine
[DOI] 10.3389/fmed.2020.569567 PMC 바로가기 [Article Type] Medicine
COVID-19-Associated Acute Limb Ischemia in a Patient on Therapeutic Anticoagulation
Internal Medicine
[키워드] acute arterial thrombosis
acute respiratory syndrome
Anticoagulant
antithrombin III
caused
Chronic kidney disease
Coagulopathy
Complication
coronavirus
Coronavirus disease 2019
COVID 19
covid coagulopathy
COVID-19
COVID-19 infection
D-dimer
deficiency
diabete
diagnosis of COVID-19
died
Disseminated intravascular coagulation
Disseminated intravascular coagulation (DIC)
element
elevated
favor
fondaparinux
Hemostatic
heparin
heparin-induced thrombocytopenia
heparin-induced thrombocytopenia (hit)
highlight
hypercoagulability
Hypercoagulable state
hyperlipidemia
hypertension
hypoxia
hypoxic respiratory failure
Ischemia
iteration
limb
mechanism
Mental
oral medications
organ system
Oxygen requirement
Patient
patients with COVID-19
performed
physical exam
Platelet
Prevent
question
raise
raising
required
resulting
SARS-CoV-2
significantly
surgical
therapeutic anticoagulation
thrombosis
virus
[DOI] 10.7759/cureus.10655 PMC 바로가기 [Article Type] Internal Medicine
[DOI] 10.7759/cureus.10655 PMC 바로가기 [Article Type] Internal Medicine